TVAX Biomedical (TVAX) Files $40M IPO
Tweet
Share
E-mail
TVAX Biomedical, Inc. (Nasdaq: TVAX), filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $40 million. TVAX plans to list on the Nasdaq Global Select market under the ticker, "TVAX."
The offering is being made through Roth Capital Partners, Cantor Fitzgerald & Co., and Morgan Joseph TriAtrisan.
TVAX is a biotechnology company focused on the development of targeted cell-based immunotherapies for the treatment of cancer.
The offering is being made through Roth Capital Partners, Cantor Fitzgerald & Co., and Morgan Joseph TriAtrisan.
TVAX is a biotechnology company focused on the development of targeted cell-based immunotherapies for the treatment of cancer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- W.R. Berkley (WRB) Reiterated at Neutral by Cantor Fitzgerald on In-Line Q2 Results
- Dyne Therapeutics prices $375M public stock offering at $20.50
Create E-mail Alert Related Categories
IPOsRelated Entities
Cantor Fitzgerald, Roth Capital, Morgan JosephSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
